X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ALEMBIC LTD Fact Sheet, ALEMBIC LTD Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD Fact Sheet   (ALMC)

Here is the latest financial fact sheet of ALEMBIC LTD. For more details, see the ALEMBIC LTD quarterly results and ALEMBIC LTD share price and chart. For a sector overview, read our pharmaceuticals sector report.

ALEMBIC LTD Price History

Price Rs 60.7
Mkt Cap Rs m 33,616
Vol '000 72.1
P/E X 122.2
P/CF X 109.1
EPS (TTM) Rs 0.5
% ch % 0.2
No. of shares m 553.80
% ch week % -2.3
% ch 1-mth % -10.2
% ch 12-mth % 52.9
52 week H/L Rs 72.0/33.9
(As on Feb 22, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ALEMBIC LTD Financials

No. of Mths
Year Ending
12
Mar-12
12
Mar-13
12
Mar-14
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
ALEMBIC LTD EQUITY SHARE DATA
High Rs4020187053 
Low Rs141471629 
Sales per share (Unadj.) Rs9.013.45.85.44.7 
Earnings per share (Unadj.) Rs-0.90.91.14.08.8 
Diluted earnings per shareRs-0.20.20.51.94.2 
Cash flow per share (Unadj.) Rs-0.11.61.24.29.0 
Dividends per share (Unadj.) Rs00.200.150.150.15 
Adj. dividends per shareRs0.000.050.070.070.07 
Dividend yield (eoy) %01.21.20.30.4 
Book value per share (Unadj.) Rs14.815.48.619.827.7 
Adj. book value per shareRs3.63.74.29.513.4 
Shares outstanding (eoy) m133.52133.52267.03267.03267.03 
Bonus/Rights/Conversions  --B1:1-- 
Price / Sales ratio x3.01.32.18.08.7 
Avg P/E ratio x-29.519.811.210.84.7 
P/CF ratio (eoy) x-283.910.610.410.24.6 
Price / Book Value ratio x1.81.11.42.21.5 
Dividend payout %023.213.63.81.7 
Avg Mkt Cap Rs m3,6052,2703,29811,46910,962 
No. of employees `000NANANANANA 
Total wages/salary Rs m255245273270238 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
ALEMBIC LTD INCOME DATA
Net Sales Rs m1,2081,7921,5361,4391,260 
Other income Rs m65103158208264 
Total revenues Rs m1,2721,8951,6941,6471,524 
Gross profit Rs m-151572239583 
Depreciation Rs m10998236061 
Interest Rs m52512380 
Profit before tax Rs m-111110335235285 
Minority Interest Rs m00000 
Prior Period Items Rs m0008252,096 
Extraordinary Inc (Exp) Rs m-25000-32 
Tax Rs m-14-539-76 
Profit after tax Rs m-1221152951,0662,343 
Gross profit margin %-1.28.714.56.66.6 
Effective tax rate %12.7-4.411.8-2.92.1 
Net profit margin %-10.16.419.274.1185.9 
ALEMBIC LTD BALANCE SHEET DATA
Current assets Rs m1,7001,2901,5431,6091,689 
Current liabilities Rs m1,6311,070907533486 
Net working cap to sales %5.712.341.474.895.4 
Current ratio x1.01.21.73.03.5 
Inventory Days Days285198248214217 
Debtors Days Days48376612281 
Net fixed assets Rs m1,9541,8841,8001,7151,624 
Share capital Rs m267267534534534 
"Free" reserves Rs m4988928743,8395,960 
Net worth Rs m1,9722,0582,3075,2787,404 
Long term debt Rs m0302331354104 
Total assets Rs m3,9153,4403,5626,1928,010 
Interest coverage x-1.13.115.429.3950.7 
Debt to equity ratio x00.10.10.10 
Sales to assets ratio x0.30.50.40.20.2 
Return on assets %-1.84.88.917.429.3 
Return on equity %-6.25.612.820.231.6 
Return on capital %-4.36.813.619.031.3 
Exports to sales %7.14.47.714.32.9 
Imports to sales %5.40.93.42.528.9 
Exports (fob) Rs m867911820537 
Imports (cif) Rs m66175237364 
Fx inflow Rs m867911820537 
Fx outflow Rs m70386342365 
Net fx Rs m164155163-328 
ALEMBIC LTD CASH FLOW
From Operations Rs m -591 803 -102 220 346 
From Investments Rs m -54 121 178 47 -48 
From Financial Activity Rs m 646 -943 -79 -250 -301 
Net Cashflow Rs m 1 -19 -3 17 -3 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 64.0%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.2%
FIIs 9.7%
ADR/GDR 0.0%
Free float 26.1%
Shareholders 54,701
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Alembic Road, Vadodara - 390 003
E-MAIL alembic.investors@alembic.co.in WEB www.alembiclimited.com
TELEPHONE (0265) 228 0550 FAX (0265) 228 2506
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, B-102-103, Shangrila Complex, 1st Flr., Akota, Vadodara-20
AUDITOR K. S. Aiyar & Co.
CHM: Chirayu R. Amin (MD) COMP SEC: Chirag K. Shukla YEAR OF INC: 1907 BSE CODE: 506235 FV (Rs): 2 DIV YIELD (%): 0.1

More Pharmaceuticals Company Fact Sheets:   AJANTA PHARMA  SANOFI INDIA  LUPIN LTD  VENUS REMEDIES  PLETHICO PHARMA  

Compare ALEMBIC LTD With:   AJANTA PHARMA  SANOFI INDIA  LUPIN LTD  VENUS REMEDIES  PLETHICO PHARMA  

Compare ALEMBIC LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC LTD

ALEMBIC LTD - LUPIN LTD COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS